Review our free webinar outlining how you can meet the February 15, 2022 reporting deadline.
The US Food and Drug Administration (FDA) has recently announced a new annual distribution report for all listed drugs. According to the FDA, “Each registrant that lists a drug must report to FDA annually on the amount of such drug that it manufactured, prepared, propagated, compounded or processed (including repacking and relabeling) for commercial distribution.” As a result, this requirement, presented with a very brief turn-around time, will affect the vast majority of the pharmaceutical industry. There are requirements surrounding the data, the submission format, and the submission pathway that need to be understood to achieve compliance with this new requirement.
In our free webinar, Reed Tech subject-matter experts, Gary Saner and David Wilson, explore what this new deadline means for pharma companies and how to ensure compliance. Review the recording from our webinar on Tuesday, February 1, 2022, at 2 PM ET to learn more.
Key Topics: • What drugs are in scope? • What drug distribution data is reported? • When must drug distribution data be reported? • Why has this requirement been introduced? • Live Q+A
Learn how to ensure you are compliant with the new FDA Drug Distribution Report.
Reed Tech is the provider of best-in-class information-based solutions and services to meet the needs of the life sciences industry, government agencies, and the intellectual property market. Our customers are located throughout the world and include a wide range of medical device manufacturers and pharmaceutical companies, the U.S. government, numerous Patent Authorities, and IP-driven companies and law firms. The corporate mission is to advance humanity by delivering better outcomes to the innovation community.